RxDoctor Payments DataLook up a doctor →

Allison Kovar, MD

Family Medicine · Onawa, IANPI 1942468111

Payments from drug & device makers

$7,008in general payments, 2019–2025

Across 490 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$838
  • Amgen$650
  • Pfizer$446
  • Astellas Pharma US Inc$327
  • E.r. Squibb & Sons, L.L.C.$297
  • plus $3K from 42 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$6,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,008 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$20,285
Medicare patients
237
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$110,855
RexultiBrexpiprazole70$85,651
OzempicSemaglutide81$78,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$77,943
RybelsusSemaglutide36$40,775
KerendiaFinerenone39$28,842
ProliaDenosumab15$25,967
GemtesaVibegron40$23,248
ArexvyRsvpref3 Antigen/As01e/Pf63$19,545
JardianceEmpagliflozin29$19,345
XareltoRivaroxaban45$19,259
MyrbetriqMirabegron29$17,464
Tresiba Flextouch U-200Insulin Degludec24$14,230
Tresiba Flextouch U-100Insulin Degludec15$10,309
LinzessLinaclotide18$9,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$838$118,820117 claims
PfizerEliquis$446$110,855156 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$230$103,185196 claims
Otsuka America Pharmaceutical, Inc.Rexulti$283$85,65170 claims
BayerKerendia$286$28,84239 claims
Boehringer IngelheimJardiance, Tradjenta$90$28,24540 claims
AmgenProlia$650$25,96715 claims
Sumitomo Pharma America, Inc.Gemtesa$143$23,24840 claims
Johnson & JohnsonXarelto$180$19,25945 claims
Astellas Pharma US IncMyrbetriq$327$17,46429 claims
AbbVieLinzess, Synthroid$1,161$10,99141 claims
AstraZenecaFarxiga$169$6,93212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Onawa

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →